• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

No evidence for oncogenic mutations in guanine nucleotide-binding proteins of human adrenocortical neoplasms.

作者信息

Reincke M, Karl M, Travis W, Chrousos G P

机构信息

Developmental Endocrinology Branch, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892.

出版信息

J Clin Endocrinol Metab. 1993 Nov;77(5):1419-22. doi: 10.1210/jcem.77.5.8077343.

DOI:10.1210/jcem.77.5.8077343
PMID:8077343
Abstract

G-Proteins are membrane-bound heterotrimeric polypeptides that couple receptor signals to second messenger systems such as cAMP. Recently, point mutations at 2 codons of the highly preserved alpha-chain of Gs, the adenyl cyclase-stimulating G-protein, were found in GH-secreting pituitary tumors. These mutations resulted in constitutively activated Gs alpha and high intracellular cAMP levels. In addition, point mutations at similar codons of a different G-protein, G(i) alpha 2, were reported in adrenocortical neoplasms, suggesting a potential role of this isoform in the genesis of these tumors. We reevaluated the frequency of constitutively activating point mutations in the alpha-chain of the stimulatory (Gs alpha) and inhibitory (G(i) alpha 2) G-proteins in human adrenocortical tumors. Seven adrenocortical carcinomas, 2 human adrenocortical tumor cell lines, and 11 adrenocortical adenomas were studied. Genomic DNA was purified from either frozen tumor tissue or paraffin-embedded sections. Using specific primers and the polymerase chain reaction, DNA fragments surrounding codons 201 and 227 (Gs alpha) and 179 and 205 (G(i) alpha 2) were amplified and visualized on a 2% agarose gel. In a second asymmetric polymerase chain reaction, using nested primers, single stranded DNA was generated using 1-10 microL of the initial amplification mixture and directly sequenced using the dideoxy chain termination method of Sanger. We found no mutations at codons 201, 227 and 179, 205 of Gs alpha and G(i) alpha 2, respectively, in the tumors studied. We conclude that previously identified oncogenic point mutations in the stimulatory and inhibitory alpha-chain of G-proteins do not appear to be present at high frequency in adrenal neoplasms. Thus, the mechanism(s) of tumorigenesis in these tumors is different from that in GH-secreting adenomas and may involve oncogenic mutations of other cell constituents.

摘要

相似文献

1
No evidence for oncogenic mutations in guanine nucleotide-binding proteins of human adrenocortical neoplasms.
J Clin Endocrinol Metab. 1993 Nov;77(5):1419-22. doi: 10.1210/jcem.77.5.8077343.
2
p53 mutations in human adrenocortical neoplasms: immunohistochemical and molecular studies.人类肾上腺皮质肿瘤中的p53突变:免疫组织化学和分子研究
J Clin Endocrinol Metab. 1994 Mar;78(3):790-4. doi: 10.1210/jcem.78.3.8126158.
3
Oncogenic mutations of alpha-Gi2 protein are not determinant for human adrenocortical tumourigenesis.
Eur J Endocrinol. 1995 Aug;133(2):166-72. doi: 10.1530/eje.0.1330166.
4
Glycoprotein hormone alpha-subunit production in somatotroph adenomas with and without Gs alpha mutations.
J Clin Endocrinol Metab. 1992 Sep;75(3):918-23. doi: 10.1210/jcem.75.3.1517386.
5
No evidence for oncogenic mutations in the adrenocorticotropin receptor gene in human adrenocortical neoplasms.
J Clin Endocrinol Metab. 1995 Mar;80(3):875-7. doi: 10.1210/jcem.80.3.7883845.
6
Rare mutations of the Gs alpha subunit gene in human endocrine tumors. Mutation detection by polymerase chain reaction-primer-introduced restriction analysis.人类内分泌肿瘤中Gsα亚基基因的罕见突变。通过聚合酶链反应-引物引入限制性分析进行突变检测。
Cancer. 1993 Aug 15;72(4):1386-93. doi: 10.1002/1097-0142(19930815)72:4<1386::aid-cncr2820720439>3.0.co;2-j.
7
Absence of the previously reported G protein oncogene (gip2) in ovarian granulosa cell tumors.卵巢颗粒细胞瘤中不存在先前报道的G蛋白癌基因(gip2)。
J Clin Endocrinol Metab. 1996 Nov;81(11):4159-61. doi: 10.1210/jcem.81.11.8923876.
8
Screening of candidate oncogenes in human thyrotroph tumors: absence of activating mutations of the G alpha q, G alpha 11, G alpha s, or thyrotropin-releasing hormone receptor genes.
J Clin Endocrinol Metab. 1996 Mar;81(3):1134-40. doi: 10.1210/jcem.81.3.8772588.
9
Heterogeneous mutations in the gene encoding the alpha-subunit of the stimulatory G protein of adenylyl cyclase in Albright hereditary osteodystrophy.奥尔布赖特遗传性骨营养不良症中腺苷酸环化酶刺激性G蛋白α亚基编码基因的异质性突变。
J Clin Endocrinol Metab. 1993 Jun;76(6):1560-8. doi: 10.1210/jcem.76.6.8388883.
10
Activating mutation of the stimulatory G protein (gsp) as a putative cause of ovarian and testicular human stromal Leydig cell tumors.刺激性G蛋白(gsp)的激活突变作为人类卵巢和睾丸间质Leydig细胞瘤的一个假定病因。
J Clin Endocrinol Metab. 1998 Jun;83(6):2074-8. doi: 10.1210/jcem.83.6.4847.

引用本文的文献

1
Mutation analysis of inhibitory guanine nucleotide binding protein alpha (GNAI) loci in young and familial pituitary adenomas.青年及家族性垂体腺瘤中抑制性鸟嘌呤核苷酸结合蛋白α(GNAI)基因座的突变分析
PLoS One. 2014 Oct 7;9(10):e109897. doi: 10.1371/journal.pone.0109897. eCollection 2014.
2
Suppression of GNAI2 message in ovarian cancer.卵巢癌中GNAI2信息的抑制
J Ovarian Res. 2014 Jan 14;7:6. doi: 10.1186/1757-2215-7-6.
3
Genetic background of adrenocortical tumor development.肾上腺皮质肿瘤发生的遗传背景。
World J Surg. 2001 Jul;25(7):948-56. doi: 10.1007/s00268-001-0034-3.
4
Expression of adrenocorticotropin receptor gene in adrenocortical adenomas from patients with Cushing syndrome: possible contribution for the autonomous production of cortisol.库欣综合征患者肾上腺皮质腺瘤中促肾上腺皮质激素受体基因的表达:对皮质醇自主分泌的可能作用。
Ann Surg. 2001 Jul;234(1):85-91. doi: 10.1097/00000658-200107000-00013.
5
Point mutations of ras genes in human adrenal cortical tumors: absence in adrenocortical hyperplasia.人类肾上腺皮质肿瘤中ras基因的点突变:肾上腺皮质增生中不存在。
World J Surg. 1994 Jul-Aug;18(4):455-60; discussion 460-1. doi: 10.1007/BF00353735.